Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 12/20 | 0.43 |
| ▸ | THRB | P10828 | 12/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255051 | 0.82 | THRB (0.48) | SMN1; SMN2THRATHRB | |
| SCHEMBL7251517 | 0.82 | THRB (0.45) | MAPTALDH1A1KMT2ATHRATHRB | |
| SCHEMBL5283826 | 0.81 | THRB (0.60) | THRATHRB | |
| SCHEMBL5282025 | 0.80 | THRB (0.52) | ALDH1A1HTTTHRATHRB | |
| SCHEMBL12312625 | 0.80 | MAPT (0.41) | MAPTSMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL5406458 | 0.80 | THRB (0.65) | THRATHRB | |
| SCHEMBL8237704 | 0.79 | SMN1; SMN2 (0.48) | MAPTSMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL7250246 | 0.79 | MEN1 (0.46) | MAPTSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL13788653 | 0.78 | THRB (0.48) | THRATHRB | |
| SCHEMBL12312629 | 0.77 | POLB (0.59) | MAPTSMN1; SMN2ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | MAPT 4442/4885SMN1; SMN2 4781/4885ALDH1A1 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.